GUO Dongjie,LI Pengmei,CHEN Wenqian,et al.A real-world survey of the effect of voriconazole on tacrolimus blood concentration after lung transplantation[J].ZHONGGUO YAOFANG,2023,34(20):2519-2524.
GUO Dongjie,LI Pengmei,CHEN Wenqian,et al.A real-world survey of the effect of voriconazole on tacrolimus blood concentration after lung transplantation[J].ZHONGGUO YAOFANG,2023,34(20):2519-2524. DOI: 10.6039/j.issn.1001-0408.2023.20.13.
A real-world survey of the effect of voriconazole on tacrolimus blood concentration after lung transplantation
To provide a reference for the dose adjustment of tacrolimus in patients who underwent lung transplantation after combined use of voriconazole.
METHODS
2
The clinical data of lung transplantation patients who used voriconazole and tacrolimus in our hospital from January 2020 to December 2022 were collected retrospectively. The effects of voriconazole on the valley concentration, daily dose and standardized blood concentration of tacrolimus were analyzed by using SPSS 21.0 software; multiple linear regression analysis was conducted for the factors that may affect the standardized blood concentration of tacrolimus.
RESULTS
2
A total of 153 lung transplantation patients were included. After the combination of voriconazole, the average daily dose of tacrolimus decreased from 3.37 mg to 0.76 mg, and valley concentration and standardized blood concentration were increased significantly (
P
<0.000 1). The average daily dose of voriconazole was negatively correlated with the standardized blood drug concentration of tacrolimus (
P
=0.000 1,
r
=-0.224). The valley concentration of voriconazole was positively correlated with valley concentration (
P
<0.000 1,
r
=0.316) and standardized blood concentration (
P
<0.000 1,
r
=0.249) of tacrolimus. After combination with voriconazole, the standardized blood drug concentration of patients who underwent single lung transplantation was significantly higher than those who underwent double lung transplantation, and the standardized blood concentration of tacrolimus after oral administration of voriconazole was significantly higher than after intravenous drip of voriconazole (
P
<0.05). Most liver and kidney function indicators showed no significant changes. The results of multiple factor regression analysis showed that the valley concentration of voriconazole had a significant impact on the standardized blood concentration of tacrolimus (
P
<0.001).
CONCLUSIONS
2
The valley concentration of voriconazole has greatest influence on the blood concentration and dose adjustment of tacrolimus, which is an independent influencing factor. In clinical practice, the dose of tacrolimus should be reduced in combination with voriconazole, and therapeutic drug monitoring should be conducted for both drugs.
关键词
伏立康唑他克莫司肺移植血药浓度治疗药物监测
Keywords
tacrolimuslung transplantationblood concentrationtherapeutic drug monitoring
references
CHAMBERS D C,CHERIKH W S,GOLDFARB S B,et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation:thirty-fifth adult lung and heart-lung transplant report-2018;focus theme:multiorgan transplantation[J]. J Heart Lung Transplant,2018,37(10):1169-1183.
SINGER J P,SINGER L G. Quality of life in lung transplantation[J]. Semin Respir Crit Care Med,2013,34(3):421-430.
NEOFYTOS D,FISHMAN J A,HORN D,et al. Epide-miology and outcome of invasive fungal infections in solid organ transplant recipients[J]. Transpl Infect Dis,2010,12(3):220-229.
HUSAIN S,CAMARGO J F. Invasive aspergillosis in solid-organ transplant recipients:guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant,2019,33(9):e13544.
HOSSEINI-MOGHADDAM S M,OUÉDRAOGO A,NAYLOR K L,et al. Incidence and outcomes of invasive fungal infection among solid organ transplant recipients:a population-based cohort study[J]. Transpl Infect Dis,2020,22(2):e13250.
PAPPAS P G,ALEXANDER B D,ANDES D R,et al. Invasive fungal infections among organ transplant reci-pients:results of the Transplant-Associated Infection Surveillance Network(TRANSNET)[J]. Clin Infect Dis,2010,50(8):1101-1111.
IMAMURA C K,FURIHATA K,OKAMOTO S,et al. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole[J]. J Clin Pharmacol,2016,56(4):408-413.
GROLL A H,TOWNSEND R,DESAI A,et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4[J/OL]. Transpl Infect Dis,2017,19(5)(2017-09-28)[2023-03-01]. https://pubmed.ncbi.nlm.nih.gov/28722255/.DOI:10.1111/tid.12751https://pubmed.ncbi.nlm.nih.gov/28722255/.DOI:10.1111/tid.12751.
WANG X X,CHEN W Q,LIU H F,et al. Quantification of voriconazole in human plasma by UPLC-MS/MS and its application in therapeutic drug monitoring[J]. China Pharmacist,2019,22(7):1189-1192.
BRUNET M,VAN GELDER T,ÅSBERG A,et al. Therapeutic drug monitoring of tacrolimus-personalized therapy:second consensus report[J]. Ther Drug Monit,2019,41(3):261-307.
CHEN W Q,ZHANG L,ZHANG Y,et al. Expert consensus on individual treatment of tacrolimusin solid organ transplantation[J]. Eval Anal Drug Use Hosp China,2021,21(12):1409-1424.
PATTERSON T F,3rdTHOMPSON G R,DENNING D W,et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Di-seases Society of America[J]. Clin Infect Dis,2016,63(4):e1-e60.
KULKARNI H S,WITT C A. Voriconazole in lung transplant recipients: how worried should we be?[J]. Am J Transplant,2018,18(1):5-6.
CHANG H H,LEE N Y,KO W C,et al. Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis[J]. Int J Infect Dis,2010,14(4):e348-e350.
SUETSUGU K,MORI,YAMAMOTO N,et al. Impact of CYP3A5,POR,and CYP2C19 polymorphisms on trough concentration to dose ratio of tacrolimus in allogeneic hematopoietic stem cell transplantation[J]. Int J Mol Sci,2019,20(10):2413.
VANHOVE T,BOUWSMA H,HILBRANDS L,et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ reci-pients[J]. Am J Transplant,2017,17(9):2372-2380.
MORI T,KATO J,YAMANE A,et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation[J]. Int J Hematol,2012,95(5):564-569.
VENKATARAMANAN R,ZANG S M,GAYOWSKI T,et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes[J]. Antimicrob Agents Chemother,2002,46(9):3091-3093.
ZHAO Y C,XIAO C L,HOU J J,et al. The effect of voriconazole on tacrolimus in kidney transplantation reci-pients:a real-world study[J]. Pharmaceutics,2022,14(12):2739.
CHEN W Q,WANG X X,LI B,et al. Effects of vorico-nazole exposure on the pharmacokinetics of tacrolimus in lung transplantation patients,based on therapeutic drug monitoring data[J]. J Clin Pharmacol,2022,62(10):1310-1320.
HOHMANN N,KOCHEISE F,CARLS A,et al. Dose-dependent bioavailability and CYP3A inhibition contri-bute to non-linear pharmacokinetics of voriconazole[J]. Clin Pharmacokinet,2016,55(12):1535-1545.
JOHNSON T N,SALEM F,JAMEI M,et al. Prediction of voriconazole non-linear pharmacokinetics using a paediatric physiologically based pharmacokinetic modelling approach[J]. Clin Pharmacokinet,2015,54(5):567-568.
KIM Y,RHEE S J,PARK W B,et al. A personalized CYP2C19 phenotype-guided dosing regimen of vorico-nazole using a population pharmacokinetic analysis[J]. J Clin Med,2019,8(2):227.
WEHBE E,DUNCAN A E,DAR G,et al. Recovery from AKI and short- and long-term outcomes after lung transplantation[J]. Clin J Am Soc Nephrol,2013,8(1):19-25.
SIKMA M A,HUNAULT C C,VAN DE GRAAF E A,et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury[J]. Eur J Clin Pharmacol,2017,73(5):573-580.
ZAPATA C M,IBRAHIM H N. Kidney disease after heart and lung transplantation[J]. Methodist Debakey Cardiovasc J,2022,18(4):34-40.
PLOSKER G L,FOSTER R H. Tacrolimus:a further update of its pharmacology and therapeutic use in the ma-nagement of organ transplantation[J]. Drugs,2000,59(2):323-389.
Research progress in pharmacokinetics and therapeutic drug monitoring of tyrosine kinase inhibitors in the treatment of gastrointestinal stromal tumors
Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors
Research progress in pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of biapenem
Research progress in pharmacokinetics/pharmacodynamics and drug use of meropenem in special population
Multi-centre survey and analysis of individual therapy of antimicrobial agents in children
Related Author
SUN Luning
WANG Yongqing
LIU Yi
ZHAO Yang
HUANG Qiongye
DONG Lin
SHU Yishuo
DONG Zhonghua
Related Institution
Clinical Pharmacology Center, the First Affiliated Hospital of Nanjing Medical University
School of Pharmacy, Nanjing Medical University
Dept. of Hematology, the First Affiliated Hospital of Shandong First Medical University(Shandong Provincial Qianfoshan Hospital)
Dept. of Clinical Pharmacy, the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)/Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and Development/Shandong Medicine and Health Key Laboratory of Clinical Pharmacy
Dept. of Pediatrics, the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)/Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and Development